A Phase 1 interventional study of Rosuvastatin and Rosuvastatin in Hepatitis C Virus, sponsored by Tibotec Pharmaceuticals, Ireland. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-11-30.
Sponsored by Tibotec Pharmaceuticals, Ireland (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing simeprevir in Hepatitis C — none open to participants now, none under way, none of them phase 3. Simeprevir · Hepatitis C.
Among the 50 studies testing simeprevir in Hepatitis C, this one is the 32nd largest by enrollment, is one of 15 that started in 2011, is one of 25 in phase 1, and was the 23rd registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 50 studies testing simeprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
Simeprevir: first FDA approval 2013 (OLYSIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 15 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 49 across the 50 interventional studies. Of the 48 that completed or were terminated, 18 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Tibotec Pharmaceuticals, Ireland, one of the names counted as Johnson & Johnson. Under that name alone:
Tibotec Pharmaceuticals, Ireland is the lead sponsor of 77 studies on the registry; none are open to participants now.
66 studies in Hepatitis C by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 65 finished, 17 (26%) have results posted.
Among the 66 studies in Hepatitis C by Johnson & Johnson, this one is the 35th largest by enrollment of the 61 interventional ones that give a count, is one of 20 that started in 2011, is one of 37 in phase 1, and was the 32nd registered.
Johnson & Johnson’s Hepatitis C studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing simeprevir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 66 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 on the single-dose pharmacokinetics of digoxin or rosuvastatin , and the effect of a single dose of digoxin or rosuvastatin on the steady-state pharmacokinetics of TMC435. Steady state is a term that means that the drug has been given long enough so that the plasma concentrations will remain the same with each subsequent dose. TMC435 is being investigated for the treatment of chronic hepatitis C virus (HCV) infection. Pharmacokinetics (PK) means how the drug is absorbed into the bloodstream, distributed in the body, and eliminated from the body.
TMC435 is being investigated for treatment of chronic hepatitis C virus (HCV) infection, in combination with Peg-IFN (pegylated interferon) and RBV (ribavirin). Digoxin and rosuvastatin are expressed in the liver and intestine and mediate the transport of drugs out of the blood circulation. The result of this study will provide dosing recommendations for TMC435 and for digoxin, rosuvastatin, or other substrates using the same drug transporter molecules, when being coadministered. This is a Phase I, open-label (both participant and investigator know the name of the medication given at certain moment), randomized (sequence of treatment with study medications is assigned by chance), crossover trial in 32 healthy volunteers to investigate the pharmacokinetic interaction between TMC435, at steady state, and digoxin or rosuvastatin at a single dose. The volunteers will be allocated to one of two panels. In Panel 1, volunteers will receive two treatments (Trts A and B) in a randomized order. Volunteers will receive digoxin 0.25 mg once daily for 1 day (Trt A) and TMC435 150 mg once daily for 7 days (Trt B) and 0.25 mg digoxin once daily for 1 day (Trt B). In Panel 2, volunteers will receive two treatments (Trts C and D) in a randomized order. Volunteers will receive rosuvastatin 10 mg once daily for 1 day (Trt C) and TMC435 150 mg once daily for 7 days (Trt D) and rosuvastatin 10 mg once daily for 1 day (Trt D). In both panels, there will be a washout period (a period when no study drug will be taken, in order to have all the medication eliminated from the body before starting a new treatment) of at least 14 days between last intake of the study medication in one session and the first intake of study medication in the subsequent session. Pharmacokinetic profiles of all three compounds will be determined through blood samples taken at regular intervals during the study. Safety and tolerability will be assessed during the study period and during follow up. Blood and urine samples, electrocardiogram (ECG) and vital signs (blood pressure and heart rate) will be taken at screening, before medication intake on Day -1 or Day 1 (Trts A, B, C, and D), on Day 2 (Trts A and C), before medication intake and 6 hours postdose (only vital signs and ECG) on Day 7 (Trts B and D), on Day 8 (Trts B and D) and at the 2 follow up visits at 1 week and 4-5 weeks after last dose of study medication in the last session. A physical examination will be performed at screening, on Day -1 (= day before first medication intake in each session for both panels) and on Day 2 in Trts A and C, on Day -1 and on Day 8 of Trts B and D and during the 2 follow-up visits. Each volunteer is part of one panel and follows 2 treatment (Trt) periods, which are a minimum 14 days apart from each other. Trt period for Trts A and C - 5 days; Trt period for Trts B and D - 11 days. Trt A and B = Panel 1, Trt C and D = Panel 2. A single, oral dose of digoxin (0.25 mg) or rosuvastatin (10 mg) to be given in Trt A or Trt C, respectively. Multiple doses of TMC435 (150 mg) for 7 days to be given in TrtB and D, with a single dose of digoxin or rosuvastatin on Day7, respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TMC435 One 150-mg capsule once daily for 7 days (Trts B and D).
Drug: TMC435
Digoxin One 0.25-mg tablet for 1 day (Trt A)
Drug: Digoxin
Digoxin One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
Drug: Digoxin
Rosuvastatin One 10-mg tablet for 1 day (Trt C).
Drug: Rosuvastatin
Rosuvastatin One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
Drug: Rosuvastatin
One 10-mg tablet for 1 day (Trt C).
One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
One 150-mg capsule once daily for 7 days (Trts B and D).
One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
One 0.25-mg tablet for 1 day (Trt A)
Change in absorption of TMC435 following co-administration with Digoxin (Panel 1).
Time frame: Measured on Days 1, 5-11 (Trt B). Reference for TMC435 is from historical data.
Change in absorption of Digoxin following co-administration with TMC435 (Panel 1).
Time frame: Measured on Day 7-11 (Trt B). Reference for Digoxin is on Day 1-5 of Trt A.
Change in absorption of TMC435 following co-administration with rosuvastatin (Panel 2).
Time frame: Measured on Day 1, 5-11 (Trt D). Reference for TMC435 are historical data.
Change in absorption of rosuvastatin following co-administration with TMC435 (Panel 2).
Time frame: Measured on Day 7-11 (Trt D). Reference for rosuvastatin is on Days 1-5 of Trt C.
Number of participants with adverse events as a measure of safety and tolerability - TMC435 and Digoxin
Time frame: 51 to 56 days (until and including last safety follow-up visit) for Panel 1
Number of participants with adverse events as a measure of safety and tolerability - TMC435 and rosuvastatin
Time frame: 51 to 56 days (until and including last safety follow-up visit) for Panel 2
No study locations are listed for this record.
The record gives a start of Jan 2011, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rosuvastatin · Simeprevir · Digoxin
Tibotec Pharmaceuticals, Ireland →